As a result, targeting insulin actions, particularly in the hypothalamus, seems to be a viable therapeutic method for treating obesity-related disorders, such as irregularities in hunger phenomena, increased HGP, and dyslipidemia. The gene discussed is INS; the disease is metabolic syndrome.